Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Zadnik Vesna) .

1 - 10 / 93
First pagePrevious page12345678910Next pageLast page
1.
Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
Mirta Koželj, Samo Zver, Vesna Zadnik, 2013, original scientific article

Abstract: Background. Tandem autologous hematopoietic stem cell transplantation (ta-HSCT) is a standard treatment for multiple myeloma (MM). Patients receive a high-dose cyclophosphamide (CY), followed by two myeloablative cycles of melphalan (MEL). There are scarce data about long term cardiotoxicity. Patients and methods. We studied 12 patients (62.25 8.55 years) six years after the completion of MM treatment with ta-HCST. Late cardiotoxic effects were evaluated clinically and echocardiographically. Results. None of the patients developed clinical signs of heart failure, all were in sinus rhythm and NT-pro BNP concentration was elevated (778 902.76 pg/mL). The left ventricular (LV) size remained normal. The LV ejection fraction did not decrease (73.75 5.67%, 69.27 6.13%, p = NS). The LV diastolic function parameters (E, A, ratio E/A and A/a) did not change significantly. In tissue Doppler parameters we observed a nonsignificant decrease in Em (10.26 2.63 cm/s, 7.57 1.43 cm/s) and Sm velocities (8.7 0.87 cm/s, 7.14 1.17 cm/s, p = NS). The E/Em values were in an abnormal range (8.66 1.05, 10.55 2.03). Conclusions. The treatment of MM with ta-HSCT, during which patients receive a high dose CY followed by two myeloablative cycles of MEL, causes mild, chronic, partially reversible and clinically silent cardiotoxic side-effects. However, ta-HSCT in patients with MM is a safe regarding cardiotoxic side effects, but, because of increasing life expectancy needs long term attention.
Keywords: cardiotoxicity, echocardiography, myeloma
Published in DiRROS: 22.03.2024; Views: 42; Downloads: 17
.pdf Full text (288,46 KB)

2.
Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma
Nebojša Glumac, Marko Hočevar, Vesna Zadnik, Marko Snoj, 2012, original scientific article

Abstract: The aim of the study was to determine whether the presence of inguinal sentinel lymph node (SLN) metastases smaller than 2 mm (micrometastases) subdivided according to the number of micrometastases predicts additional, non-sentinel inguinal, iliac or obturator lymph node involvement in completion lymph node dissection (CLND). Positive inguinal SLN was detected in 58 patients (32 female, 26 male, median age 55 years) from 743 consecutive and prospectively enrolled patients with primary cutaneous melanoma stage I and II who were treated with SLN biopsy between 2001 and 2007. Micrometastases in inguinal SLN were detected in 32 patients, 14 were single, 2 were double, and 16 were multiple. Twenty-six patients had macrometastases. No patient with any micrometastases or a single SLN macrometastasis in the inguinal region had any iliac/obturator non-sentinel metastases after CLND in our series. Furthermore, no patient with single SLN micrometastasis in the inguinal region had any non-sentinel metastases at all after CLND in our series. In these cases respective CLND might be omitted.
Published in DiRROS: 21.03.2024; Views: 48; Downloads: 20
.pdf Full text (307,79 KB)

3.
The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice
Brigita Gregorič, Vesna Zadnik, Barbara Jezeršek Novaković, 2012, original scientific article

Abstract: Background. Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial treatment of these patients. However, the treatment recommendations are based on resultsof clinical studies while the conditions of routine treatment are far different from the ones in clinical studies. The aim of this retrospective study was therefore to compare the treatment results of routinelz treated patients with the DLBCL to results reported by some larger studies. Patients and methods. Two hundred and ninety five patients with the DLBCL were treated between 2004 and 2008 according to the then protocol with R-CHOP or R-CHOP-like regimens at the Institute of Oncology Ljubljana. Treatment response was evaluated according to Chesonʼs criteria and the disease-free andoverall survival by means of Kaplan Meier survival curves. Results. Response to treatment in our evaluation diverged from the reported one predominately in the low risk group (international prognostic index [IPI] categorisation) and in the very good prognosis group (revised international prognostic index (R-IPI) categorisation). The determined complete response (CR) rates in other IPI and R-IPI groups were generally within expectations. Also in the disease-free survival the largest discrepancy occurred in the low-risk patient group (3 year disease-free survival rate of 75%) and in the very good prognosis group (4 year disease-free survival rate of 59%). In all other IPI risk groups, the disease-free survival at 3 zears (low intermediate risk 76%, high intermediate risk group 57%, and high risk group 53%) agreed verz well with the quoted ones. Slightly worse was the compliance of the 4 year disease-free survival rates (72% in the good prognosis and 51% in the poor prognosis group) with the results from the literature. The 3 year overall survival rates (low risk patients 87%, high intermediate risk 61% and high risk patients 51%) were somewhat worse than the reported ones in all IPI subgroups except in the low intermediate risk group (82%). On the other hand, the 4 year overall survival rates of the R-IPI categories (94% in the very good prognosis group, 80% in the good prognosis group, 56% in the poor prognosis group) were much better correlated with the data from the literature. Conclusions. In total, the treatment outcomes of routinely treatedpatient with the DLBCL at our institute are quite encouraging when compared to results of some larger studies. There are probably no dilemmas about how to treat young good prognosis patients and patients aged over 60 years at present. However, the 5 year overall survival rate of 76% for the young poor prognosis group is unsatisfying and needs to be improved. At present, quite a few studies are underway to clarify which of the regimens will perform best in this population.
Keywords: diffuse large B-cell lymphoma, R-CHOP, treatment result, routine treatments
Published in DiRROS: 21.03.2024; Views: 58; Downloads: 24
.pdf Full text (621,34 KB)

4.
Incidenca raka v prvem letu epidemije covida-19
Vesna Zadnik, Tina Žagar, Nika Bric, Mojca Birk, Amela Duratović Konjević, Ana Mihor, Katarina Lokar, Sonja Tomšič, 2023, professional article

Abstract: Uvod: Število novih diagnoz raka (incidenca) se v Sloveniji v zadnjem desetletju povečuje za povprečno 1,6 % na leto. V letu 2020, prvem letu omejitvenih ukrepov zaradi epidemije covida19, smo s platformo OnKOvid predvideli 3–8-odstotni padec novih diagnoz raka. Namen je predstaviti uradno incidenco raka za Slovenijo za leto 2020 in ugotoviti, kolikšen je bil dejansko manko novih diagnoz raka. Metode: V Registru raka Republike Slovenije smo v skladu z mednarodnimi pravili registrirali vse nove primere raka pri prebivalcih s stalnim prebivališčem v Sloveniji. Primerjali smo jih z registrirano incidenco za 2019, modelno incidenco za 2020, preliminarnimi rezultati OnKovida in dostopnimi rezultati incidence iz registrov raka iz drugih držav. Rezultati: V letu 2020 je za rakom zbolelo 15.096 oseb v Sloveniji (7.034 žensk, 8.002 moška). Glede na modelno oceno incidence za leto 2020 gre za manko 1.854 oseb (10,9 %; 11,6 % žensk, 10,4 % moških). Pri tem je za 10,5 % manj ugotovljenih rakov v omejenem stadiju, najbolj izrazito v starosti 50–69 let (za 13,2 %). Upad je primerljiv s poročili iz Anglije, ZDA in Kanade ter deloma večji kot na Škotskem in Švedskem. Najbolj izrazit upad novih diagnoz raka ugotavljamo pri nemelanomskem kožnem raku (23 %, najbolj po 50. letu), raku prostate (15,9 %, najbolj v omejenem stadiju), pljučnem raku (8,9 %, 60–64 let, v razširjenem stadiju), raku dojk (8,3 %, 45–64 let), ne-Hodgkinovem limfomu (9 %) in levkemijah (11,6 %). Pri kožnem melanomu, raku debelega črevesa in danke ni bilo primanjkljaja. Zaključek: Upad incidence raka v letu 2020 gre verjetno na račun omejitvenih ukrepov, reorganizacije zdravstva in z zdravjem povezanega vedenja med epidemijo covida-19, beležijo jo v več državah. Med epidemijami je potrebno nemoteno izvajanje onkologije.
Keywords: rak, incidenca, register raka, epidemija, covid-19
Published in DiRROS: 26.02.2024; Views: 121; Downloads: 23
.pdf Full text (301,68 KB)

5.
Complete yearly life tables by sex for Slovenia, 1982-2004, and their use in public health
Tina Žagar, Vesna Zadnik, Maja Pohar Perme, Maja Primic-Žakelj, 2006, original scientific article

Published in DiRROS: 15.02.2024; Views: 78; Downloads: 18
.pdf Full text (1,84 MB)

6.
Povezanost med rakom in onesnaževali, ki nastanejo v procesih sežiga in sosežiga odpadkov: krovni pregled literature
Teja Oblak, Tanja Carli, Vesna Zadnik, Niko Samec, Andreja Kukec, 2023, review article

Abstract: Izhodišča: V procesih sežiga in sosežiga odpadkov ter proizvodnje cementa se v okolje sproščajo izpusti, ki vsebujejo različna onesnaževala. Z namenom oceniti povezanost med rakom pri poklicno izpostavljenih in okoliških prebivalcih ter izpostavljenostjo okoljskim onesnaževalom iz sežigalnic, naprav za sosežig in cementarn smo si za cilj zadali izdelavo krovnega pregleda literature. Metode: V krovni pregled literature so bile vključene metaanalize in sistematični pregledi literature v angleščini v obdobju od leta 1980 do leta 2023. Iskanje je bilo izvedeno v štirih podatkovnih zbirkah (PubMed, Scopus, Web of Science, Cochrane Reviews). Kakovost je bila ocenjena z orodjema AMSTAR-2 (metodologija) in GRADE (dokazi). Rezultati: Izmed 7.701 opredeljenih dokumentov jih je bilo v končno analizo vključenih 14 (pet metaanaliz, devet sistematičnih pregledov). Obstajajo nizki do zmerni dokazi o povezanosti med sarkomom mehkih tkiv in ne-Hodgkinovim limfomom z izpostavljenostjo dioksinom v okolici sežigalnic I. generacije, česar študije niso dokazale za sežigalnice naslednjih generacij. Zaenkrat ne razpolagamo z dokazi za sosežig. Pri delavcih v cementarnah I. do II. generacije obstaja nekaj zmernih dokazov o povezanosti med incidenco vseh rakov, pljučnega raka, raka ustne votline in žrela, prostate in želodca z izpostavljenostjo šestvalentnemu kromu. Velika večina dokazov je omejenih zaradi mešanih rezultatov, razlik v tehniki vprašanj, heterogenosti in potencialni pristranosti. Zaključek: Obstajajo omejeni dokazi o povezanosti med rakom in izpostavljenostjo onesnaževalom iz sežigalnic I. in cementarn I. do II. generacije. Za oceno morebitne povezanosti med rakom in onesnaževali iz najsodobnejših naprav za sosežig je smiselno načrtovati ciljane epidemiološke študije in študije notranje izpostavljenosti z uporabo humanega biomonitoringa.
Keywords: rak, odpadki, sežig, sosežig, cementarna, onesnaževala
Published in DiRROS: 08.01.2024; Views: 182; Downloads: 68
.pdf Full text (189,92 KB)
This document has many files! More...

7.
Epidemiologija raka dojk
Vesna Zadnik, Sonja Tomšič, 2023, published professional conference contribution

Keywords: rak dojk, epidemiologija, register raka
Published in DiRROS: 05.01.2024; Views: 150; Downloads: 37
.pdf Full text (154,94 KB)

8.
Epidemiologija malignega melanoma
Maja Primic-Žakelj, Tina Žagar, Vesna Zadnik, 2007, published scientific conference contribution

Published in DiRROS: 06.12.2023; Views: 148; Downloads: 43
.pdf Full text (1,20 MB)

9.
Presejanje za raka materničnega vratu v Sloveniji in državni program ZORA
Maja Primic-Žakelj, Vesna Zadnik, Ana Pogačnik, Marjetka Uršič-Vrščaj, 2006, professional article

Published in DiRROS: 05.12.2023; Views: 113; Downloads: 39
.pdf Full text (345,20 KB)

10.
Epidemiologija raka dojk v svetu in v Sloveniji
Maja Primic-Žakelj, Vesna Zadnik, 2004, published scientific conference contribution

Abstract: Izhodišča. Rak dojk je v Sloveniji napogostejši rak pri ženskah. Leta 2001 je za njim zbolelo 964 žensk (94,7/100.000), pričakujemo pa, da se bo v prihodnjih desetih letih incidenca še večala. Delež rakov, odkritih v omejenemstadiju, se počasi povečuje; leta 2001 je bilo takih manj kot 50% vsehprimerov. Čeprav se je preživetje bolnic izboljšalo (72% petletno relativno preživetje bolnic z rakom, odkritim v letih 1993-97), ostaja rak dojk pri ženskah na prvem mestu med vzroki smrti zaradi raka. Med dokazane nevarnostne dejavnike sodijo poleg spola in starosti še poprejšnji rak dojk, nekatere benigne bolezni dojk, družinska obremenitev, ionizirajoče sevanje, nekateri reproduktivni dejavniki in debelost. Za številne druge pa še ni dokončnega soglasja glede vprašanja, ali so povezave, ki so jih našli v nekaterih epidemioloških raziskavah, res vzročne. V primarni preventivi zaenkrat ni posebnih priporočil, so le splošna: vzdrževanje normalne telesne teže, pravilna prehrana, telesna dejavnost in zmernost pri pitju alkoholnih pijač. Ocenjujejo, da presejanje, redno marnografsko pregledovanje žensk po 50. letu starosti, zmanjša umrljivost za rakom dojk med pregledanimi za okrog 30%. Zaključki. Problem raka dojk je mogoče reševati celostno, s primarno preventivo, zgodnjim odkrivanjem in dostopnostjo do učinkovitega zdravljenja, predvsem pa z vlaganjem sredstev tja, kjer je razmerje med stroški in koristjonajugodnejše.
Published in DiRROS: 01.12.2023; Views: 139; Downloads: 43
.pdf Full text (361,42 KB)

Search done in 0.34 sec.
Back to top